Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.93
- Piotroski Score 5.00
- Grade Overweight
- Symbol (ABBV)
- Company AbbVie Inc.
- Price $176.93
- Changes Percentage (3.03%)
- Change $5.2
- Day Low $173.57
- Day High $178.86
- Year High $207.32
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Last Earnings 10/30/2024
- Ex-Dividend for 5/16 Dividend 01/15/2025
- Dividend Payable 02/14/2025
- Today N/A
- Next Earnings (Estimated) 01/31/2025
- Fiscal Year End N/A
- Average Stock Price Target $172.00
- High Stock Price Target $226.00
- Low Stock Price Target $127.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $3.35
- Trailing P/E Ratio 50.57
- Forward P/E Ratio 50.57
- P/E Growth 50.57
- Net Income $4.86 B
Income Statement
Quarterly
Annual
Latest News of ABBV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
AbbVie Inc. is increasing its dividend to $1.64, exceeding industry averages. Despite high payouts, strong cash flows suggest sustainability. While dividend growth may be limited, AbbVie's stable trac...
By Yahoo! Finance | 5 days ago -
Why AbbVie's (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment
AbbVie stock dropped 10% after its schizophrenia drug failed in trials. Despite investor concerns, the setback is seen as a buying opportunity. AbbVie focuses on innovative medicines, with top product...
By Yahoo! Finance | 6 days ago -
AbbVie's stock plummets over 12% after schizophrenia drug flops in Phase II trials
AbbVie's stock plummeted by 12% after its anti-psychotic drug, emraclidine, failed to meet primary endpoints in Phase II trials for schizophrenia treatment....
By Yahoo! Finance | 1 week ago
